FDA Advisers Back Authorization of Novavax COVID Shot
The benefits of Novavax’s adjuvanted protein-based COVID-19 vaccine outweigh the risks, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) said in a near-unanimous vote on Tuesday. With 21 members voting yes, and one abstention, VRBPAC recommended Novavax’s two-dose vaccine for adults, saying that it met the criteria for FDA emergency use authorization (EUA). […]
Shingrix OK’d For Immunocompromised Adults
FDA expanded the approval of Shingrix, an adjuvanted recombinant zoster vaccine, for adults at increased risk of shingles due to immunosuppression, manufacturer GlaxoSmithKline (GSK) announced on Monday. The expanded indication is for adults ages 18 and older at a greater risk of shingles due to “immunodeficiency or immunosuppression caused by known disease or therapy.” The […]